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DEVELOPMENT OF AN IN VIVO ASSAY FOR DETECTION OF NON-
TARGETED RADIATION EFFECTS
Colin Seymour and Carmel Mothersill  Medical Physics and Applied Radiation
Sciences Unit, McMaster University, Hamilton, Ontario, Canada
 An adaptive response may be defined as the effect of a small priming dose of radiation
modifying the anticipated cellular response of the same tissues so as to alter the predicted
response to a larger dose of radiation. We and others have demonstrated that at low radi-
ation doses (less than 0.5 Gy) the lethal and mutational effect of the radiation is mainly,
possibly entirely, due to the non-targeted effects. This is the dose range for priming doses
in adaptive response protocols. In an associated presentation from our group, we demon-
strate that the adaptive response may be explicable as a non targeted (bystander)
response. In this paper we present data from exposed human patients, showing that a sim-
ple assay using blood can demonstrate variation in the extent and type of non-targeted
effects and that exposure to radiation can modulate the subsequent non-targeted
response to a later dose. Patients undergoing radiotherapy treatment for cancer gave
blood samples immediately after the first dose, midway during and six weeks after thera-
py. The serum from these samples was harvested, diluted in tissue culture medium and
added to reporter cells. The toxicity or growth promoting activity of the serum was meas-
ured using a clonogenic assay coupled with immunocytochemical measurement of various
proteins involved in apoptosis or growth. There is already evidence that bystander effects
are controlled by both genetic and epigenetic (lifestyle) factors. These data could support
the development of a simple blood based assay to predict overall response of human sub-
jects to low doses of radiation taking all the low dose factors into account.
I. INTRODUCTION
Radiation has been referred to in somewhat melodramatic fashion as
the invisible killer. It is regarded as invisible because it cannot be sensed
in any way. It is regarded as a killer because of the generally accepted
analysis of, and extrapolation from, the fatalities of Hiroshima and
Nagasaki.
This “invisibility” means that persons exposed to low doses do not
necessarily know they have been exposed. Moreover, if they were
exposed, they are unaware of how long they were exposed for. It would
obviously be helpful to have a biological dosimeter within the patient that
could be interrogated to reveal the nature and duration of the radiation
exposure.
This has been worked on for a number of years, under the prevailing
radiation paradigms. These paradigms are that there are target sites with-
in the cell for radiation action, and that increasing dose causes a propor-
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tional increase in effect. These paradigms are encapsulated in the linear
no-threshold model of radiation action, which extrapolates risk from
high dose acute exposure. 
It is implicit within this model that the primary lesion caused by radi-
ation is the DNA double strand break, and that these breaks are produced
in proportion to radiation dose. Theoretically, therefore, any dose of radi-
ation can cause a double strand break, and therefore there cannot be a
dose of radiation that is risk free. 
This approach is now being challenged by the emergence of a whole
body of data, which suggests that at low doses, the dose is not as impor-
tant as the response to that dose.1-4 Bystander effects, genomic instability
and adaptive responses all mean that the LNT hypothesis is too simple to
explain low dose responses. The responses appear to be both genetically
and epigenetically determined, and response does not seem to increase
with dose in any clear way.5, 6
A whole new approach is needed where the emphasis is on response
and not dose. The temporal and spatial aspects of response are also criti-
cal. The ideal biological endpoint will also distinguish between effect and
harm. 
Previous data from our group showed that tissue, harvested from
human or mouse sources and irradiated in vitro, showed considerable
variation in the degree to which bystander and genomic instability effects
were expressed.7-10 A clear genetic component can be shown using mice,7,
8 and an epigenetic component can be demonstrated by analyzing data
from smokers separately.8-10 These data lead us to suspect that a more gen-
eral in vivo test using blood might be possible.
II. THE NEW APPROACH
As an approach towards examining these issues, we have been taking
blood from radiotherapy patients. These patients are exposed daily to
doses of around 2.0 Gy, to a localized treatment area. Treatment times
vary according to machine type, but are typically around two minutes.
During this time, circulating lymphocytes will receive part of this dose as
they travel through the circulatory system. It is unusual for any areas of
bone marrow production to be directly irradiated, but both they and cir-
culating lymphocytes will receive a certain amount of scattered radiation. 
The blood from the patients is centrifuged at 1500 rpm in a bench
centrifuge, and the serum is aspirated off. 0.5 ml of this is added to flasks
(in triplicate) containing 300 human keratinocyte cells, pre-seeded in 5
ml of tissue culture medium, six hours previously. Controls are unirradi-
ated human serum samples and culture medium from irradiated and
control keratinocytes. The flasks are incubated at 37°C in a humidified
incubator, in an atmosphere of 5% CO2 in air for nine days. The flasks are
then stained with carbol fuchsin stain, and colonies are counted using the
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Puck and Markus clonogenic assay technique. The clonogenic survival is
the number of cells that form colonies and is determined by calculating
the number of colonies divided by the original number of plated cells.
This is corrected for the control plating efficiency. 
This assay effectively measures the toxicity of the serum from irradi-
ated patients towards unirradiated cells and is a bystander toxicity index
(BTI), which we define here as the toxicity of the treated sample versus
the control. An index less than one means the overall effect is toxic. If the
index is greater than one, the bystander effect causes growth or enhanced
clonogenic survival.
III. PRELIMINARY RESULTS AND DISCUSSION
Figure 1 shows the preliminary results for the first 19 patients. It is
clear there is very large individual variation in response. But this proba-
bly is due to the low patient numbers at this stage. At present, since the
patient details are coded to preserve objectivity, we have not analyzed all
the data regarding clinical radiosensitivity of these patients, but have
accumulated these data together with fatigue scores for the patients as a
generic measure of systemic response. 
Figure 2 shows the results obtained for a small subset of patients with
very advanced cancers. Three patients had primary colon tumours and
one had primary breast. They are linked by all having advanced metasta-
tic tumour spread. Clearly, their BTI is greater than one, meaning that
the bystander effect in this instance is promoting proliferation. 
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FIGURE 1. Toxicity of serum from radiotherapy patients Samples were taken at the start of radio-
therapy after the first dose had been administered. “N” is a mean control value for ten normal unir-
radiated volunteers without cancer.
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In Figure 3, data for a group of patients where three blood samples
were tested are shown. Samples were taken immediately after the first
dose, midway during therapy and six weeks after radiotherapy. Again
there is great individual variation but the trend is for the bystander effect
either to decrease during therapy in some patients or to decrease during
therapy in others. A bell shaped response only occurred in one patient.
C. Seymour and C. Mothersill
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FIGURE 2. Lack of toxicity of serum harvested from four patients who had very large tumours.
FIGURE 3. Toxicity of serum obtained from radiotherapy patients before, during and six weeks after
treatment. All data were normalized to 100% for the control. The actual mean control-plating effi-
ciency for the three time points was 24.5 + 3.7.
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Clearly again, more patient data are needed. The aim of the paper is to
show the possibilities of this assay not to draw conclusions from this lim-
ited amount of data. The data are, however consistent with other data
from our group suggesting an adaptive response to this endpoint of radi-
ation exposure.11
These results, although very preliminary, do give hope that a new bio-
logical dosimetric test, which gives useful data concerning low dose
response, can be developed.
Most tests for radiation exposure concentrate on measuring chromo-
some damage in lymphocytes,12-15 assuming that if the lymphocytes were
circulating at the time of irradiation they would have received a number
of double strand breaks proportional in some way to the absorbed dose.
If there was no proportionality between dose and double strand breaks
this may have been attributable to repair of the breaks, although repair of
some lymphocytes may be restricted. Physiology is also relevant here, as
the number of lymphocytes circulating at the time irradiation will
decrease through natural wastage. In other words, any values obtained
are useful only if the time of irradiation is known.
It would appear from our preliminary data that an ‘adaptive model’
corrects the excesses of the initial response and can be thought of as a sta-
bilizing mechanism. In other words, patients that produce an initial large
bystander effect produce an adaptive response that mitigates this. In
patients with a small bystander effect, the adaptive response produces the
opposite effect. The magnitude and direction of any adaptive response is
thus dependent on initial conditions and so might well fall into a chaotic
model.
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